002900.SZ Stock Analysis
00
Avoid
Based on Eyestock quantitative analysis, 002900.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical medicine preparations. The company is headquartered in Harbin, Heilongjiang and currently employs 1,519 full-time employees. The company went IPO on 2017-09-22. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The firm's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The firm mainly distributes its products within domestic market.